ProShares Ultra Nasdaq Biotechnology (BIB)
BIB Price and Sentiment
BIB Latest news
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This follows the Monday news that the FDA fully approved the Pfizer and BioNTech COVID-19 vaccine, making it the first vaccine in the U.S. [.
Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that officials are hoping will encourage those who have been reluctant to receive a vaccine to get vaccinated.
There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be awarded such a designation. The move could generate additional confidence for more businesses, schools, and universities to embrace the current vaccine mandates.
As the Delta variant sweeps across the globe, pharmaceutical and biotech companies are working to ensure vaccines continue to cover the population, as well as working on booster doses that can adapt to future mutations. “Delta has gone the way we were hoping it wouldn't.
We highlight a few leveraged ETF areas that won last week.
From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.